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Abstract
Aims Cardiopulmonary exercise test (CPET) provides parameters such as peak VO2 and ventilation/CO2 production (VE/
VCO2) slope, which are strong prognostic predictors in patients with stable advanced chronic heart failure (ADHF). The study
aim was to evaluate the effects of the inodilator levosimendan on CPET in patients with ADHF under stable clinical conditions.
Methods and results We enrolled patients with ADHF (peak VO2< 12mL/min/kg) in a double-blind, placebo-controlled pro-
tocol. Patients were randomly assigned to i.v. infusion of placebo (500mL 5% glucose; n = 19) or levosimendan (in 500mL 5%
glucose; n = 23). Before and 24 h after the end of the infusion, patients underwent determination of New York Heart Associ-
ation class, B-type natriuretic peptide (BNP), haemoglobin, serum creatinine, and blood urea nitrogen levels, as well as CPET,
standard spirometry, and alveolar capillary gas diffusion. BNP showed no change with placebo (1042 ± 811 to 1043
± 867 pg/mL), but it was decreased with levosimendan (1163 ± 897 to 509 ± 543 pg/mL, P< 0.001). No changes were observed
for haemoglobin, creatinine, and blood urea nitrogen in either group. With levosimendan, a minor improvement was observed
in spirometry measurements, but not in alveolar capillary gas diffusion. Peak VO2 showed a small, non-signiﬁcant increase with
placebo (9.5 ± 1.7 to 10.0 ± 2.1mL/kg/min, P = 0.12), and a greater increase with levosimendan (9.8 ± 1.7 to 11.0 ± 1.9mL/kg/
min, P< 0.005). The VE/VCO2 slope showed no change (44.0 ± 11 vs. 43.4 ± 10.3, P = 0.44), and a decrease (41.9 ± 10 vs.
36.6 ± 6.4, P< 0.001) in the placebo and in the levosimendan group, respectively.
Conclusion Levosimendan treatment signiﬁcantly improves peak VO2 and reduces VE/VCO2 slope and BNP in patients with
ADHF.
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Introduction
The efﬁcacy of any treatment for heart failure (HF) is
assessed according to both patient survival and quality of life,
and through several analytical tools, which include labora-
tory, functional, and exercise-derived parameters.1 As well
as providing clinical efﬁcacy, which is a qualitative evaluation,
this has allowed a more quantitative and objective analysis.
Among the different functional techniques, cardiopulmonary
exercise test (CPET) provides multiple parameters, such as ox-
ygen consumption (VO2) both at peak exercise and at anaer-
obic threshold, and the ventilatory equivalent ratio for
carbon dioxide [i.e. ventilation vs. carbon dioxide production
(VE/VCO2)]. VE/VCO2 is either determined as the ratio or as
the slope of the relationship, and, along with VO2, it is used
to estimate the prognosis of patients with HF,2–4 to evaluate
the efﬁcacy of any therapy,3 and to determine the way in
which any intervention is effective.3 Spirometry and
alveolar–capillary membrane diffusion, which is usually calcu-
lated as the carbon monoxide diffusing capacity (DLCO), are
frequently combined with CPET to allow a more complete in-
terpretation of CPET data. Of note, DLCO per se provides in-
formation on patient prognosis and on the mechanisms of
drug action.5–7
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In contrast, in acute HF, the efﬁcacy of therapy is usually
evaluated only in terms of survival, hospital stay, quality of
life, haemodynamic measurements, and possible laboratory
data, such as B-type natriuretic peptide (BNP) levels.8,9 How-
ever, these data are frequently inconsistent, and their inter-
pretation can be difﬁcult. For instance, repetitive and
prolonged administration of clinical inotropes, such as dobu-
tamine and milrinone, has been associated with favourable
haemodynamic changes and symptom improvement,10 al-
though serious safety concerns have emerged.11 In particular,
two meta-analyses of randomized trials of β-adrenergic ago-
nists and phosphodiesterase inhibitors have suggested that,
despite acute clinical and haemodynamic improvements,
there is increased mortality.12,13
The inodilator levosimendan combines positive inotropic,
vasodilatory, and cardioprotective effects, without evoking
signiﬁcant changes in myocardial oxygen requirements,14–16
and it has been shown to improve symptoms and
haemodynamics in patients with acute HF.17 Phase III clinical
studies with levosimendan have shown encouraging results in
patients with acute HF.8,18,19 Some studies have suggested
that levosimendan can reduce mortality in this setting,20,21 al-
though the evidence is not uniform.22,23 An expert panel re-
cently suggested that, based on the existing evidence,
levosimendan might also be used in patients with advanced
chronic HF (ADHF),24 although no evaluation of the effects
of levosimendan on CPET parameters and DLCO has ever
been carried out in this setting. Such an investigation would
provide relevant information for the evaluation of
levosimendan efﬁcacy in patients with ADHF and possibly
also provide some mechanistic information. We therefore
analysed the effects of levosimendan infusion on CPET, stan-
dard spirometry, DLCO, and BNP values in a population of pa-
tients with ADHF who could tolerate an exercise test, with a
peak VO2< 12mL/min/kg. The BNP values were used as an
index of patients’ haemodynamic status.1,9
Methods
Patient selection
The present study was a single-centre, double-blinded,
placebo-controlled, randomized trial, and it has been regis-
tered at clinicaltrials.gov as NCT02261948.
Eligible patients had ADHF according to the European Soci-
ety of Cardiology (ESC) deﬁnitions.1 Speciﬁcally, patients had
severe HF symptoms [New York Heart Association (NYHA)
classes III to IV], multiple episodes of ﬂuid retention and/or pe-
ripheral hypoperfusion, and objective evidence of severe cardiac
dysfunction. Moreover, patients had severe impairment of
functional capacity, history of>1 HF hospitalizations in the past
6months, and the presence of all the previous features despite
optimal therapy.1 The infusions started approximately 3h after
the clinical, blood, and spirometry tests had been completed,
which means after 48 to 72h of clinical stabilization.
In the present study, patients were hospitalized for wors-
ening HF, but, when recruited for the study, they had been
returned to a stable clinical condition (NYHA III–IV), and they
had been free from both inotrope support and other i.v. ther-
apies, such as nitrate, nitroprusside, or dobutamine, for at
least 48 h prior to study inclusion, except for diuretics where
needed. The study inclusion criteria were a follows: left ven-
tricular ejection fraction at echocardiography ≤35%, age
≥18 years, capability to perform CPET, peak VO2< 12mL/
min/kg, peak respiratory quotient >1.05, and standard HF
therapy.
The exclusion criteria were as follows: ongoing mechanical
ventilation; recent or acute coronary and respiratory syn-
dromes; recent sustained ventricular tachycardia or ventricu-
lar ﬁbrillation; severe aortic or mitral valve disease, or known
malfunctioning artiﬁcial heart valve; uncorrected obstructive
valvular disease; hypertrophic cardiomyopathy; and uncor-
rected thyroid disease, or presence of any disease that might
per se inﬂuence exercise performance. Patients with left ven-
tricle assist devices, patients with a pacemaker-guided heart
rate at rest or during exercise, and patients in which
levosimendan is contraindicated were also excluded. Finally,
patients who had received levosimendan in the previous
6months were excluded.
Patients were enrolled by speciﬁc study investigators (SM,
PA), with randomization to placebo or levosimendan carried
out by a designated employee of the hospital’s pharmacy de-
partment who was not aware of the patients’ data. The
placebo and active drug infusions were indistinguishable,
and both patients and investigators were blinded to treat-
ment allocation. In parallel with the placebo infusion
(500mL 5% glucose solution), the active treatment
(levosimendan 12.5mg in 500mL 5% glucose solution) was
infused after 48 h of stable conditions, starting at 0.05μg/
kg/min (starting dose), and progressively increased up to
0.2μg/kg/min, based on patient clinical status and blood
pressure, until the entire infusion had been administered.
The protocol was approved by the Institutional Ethics
Board (Cardiology Centre Ethical Committee, N° S199/312),
and it was performed in compliance with institutional guide-
lines and with the Declaration of Helsinki. All patients pro-
vided written informed consent before entering the study.
Study procedures
A scheme of the study procedures is shown in Figure 1. All
patients belonged to a cohort of HF patients regularly
followed at our HF Unit. The patients had initially been hospi-
talized for worsening of their HF, and they were invited to
participate in the study once they had been stabilized for at
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least 24 h, if they fulﬁlled the study inclusion/exclusion
criteria. Their complete medical history, physical examina-
tion, and blood sample tests were recorded both before the
treatment infusions and 24 h after the end of the treatment
infusions, and the following were included: NYHA class,
BNP, haemoglobin and creatinine levels, and blood urea ni-
trogen. Two-dimensional standard echocardiography evalua-
tion was also performed. Standard spirometry and DLCO
measurements were performed before and 24 h after the
treatment infusions, always before CPET. Forced expiratory
volume in 1 s (FEV1) and vital capacity were measured in trip-
licate and calculated according to the American Thoracic So-
ciety criteria,25 using a mass ﬂow sensor (SensorMedics
2200, Sensor Medics Co., Yorba Linda, CA, USA). DLCO was
measured by the single-breath constant-expiratory-ﬂow tech-
nique (SensorMedics 229D, Sensor Medics Co.26). Dilution of
CH4 was used to measure alveolar volume.
All patients had previously performed at least one CPET,
which is routinely performed in our HF clinical follow-up pro-
gramme to optimize patient follow-up. The prior CPET com-
bined with the clinical conditions upon study entry was
used to choose patients’ personalized ramp exercise proto-
col, which was aimed at achieving peak exercise in 10min.27
CPET was performed on a cycle ergometer (SensorMedics
Ergo 800S, Sensor Medics Co.) before and 24 h after treat-
ment infusions. If the exercise duration was <7min, the CPET
was repeated the following day; in these cases, the labora-
tory measurements were also repeated. Expiratory O2, CO2,
and VE were measured breath by breath (Vmax 229D, Sensor
Medics Co.). Peak VO2 was considered as the highest VO2
achieved during the exercise (mean, 20 s). The anaerobic
threshold was measured as the V-slope analysis of the plot
for carbon dioxide production (VCO2) vs. VO2, on equal
scales,28 and conﬁrmed by changes in the ventilatory equiva-
lent and end-tidal oxygen pressure and carbon dioxide pres-
sure (PetCO2). The VO2 vs. work-rate relationship was
calculated throughout the exercise. The VE vs. VCO2 relation-
ship was calculated as the slope of the linear relationship be-
tween VE and VCO2 from the beginning of the loaded
exercise to the end of the isocapnic buffering period. The ra-
tios between VE and VCO2 and VO2 were calculated at the an-
aerobic threshold.29 Oxygen pulse was calculated as VO2/
heart rate. Exercise-induced periodic breathing was deﬁned
as a cyclic ﬂuctuation of ventilation during exercise.30
Twelve-lead electrocardiograms were also continuously re-
corded (Case 800, Marquette, Milwaukee, WI, USA). Blood
pressure was measured during CPET every 2min, by
sphygmomanometer.
Study endpoints
The primary endpoint was peak VO2 changes after the pla-
cebo and levosimendan infusions. The secondary endpoints
were changes in BNP and VE/VCO2 slope after the treatment
administrations.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 software
(SPSS Inc, Chicago, IL, USA). Continuous variables were
expressed as means ± standard deviation (SD), and discrete
variables as absolute numbers and percentages. Comparisons
between the two treatment groups at baseline were per-
formed using unpaired t-tests for normally distributed vari-
ables, and Mann–Whitney U-test for non-normally
distributed variables. P< 0.05 was considered statistically sig-
niﬁcant. Differences between the effects of infusion in the
two treatment groups were assessed by computing the inter-
action term (infusion × treatment) in a repeated measures
Figure 1 Scheme of the study protocol. CPET, cardiopulmonary exercise
test; PFT, Pulmonary Function Test; HF, heart failure; DLCO, carbon
monoxide diffusing capacity.
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analysis of covariance. Correlations between changes in BNP,
peak VO2, and the other evaluated parameters were investi-
gated using linear regression analysis. The required sample
size was determined as 42, to be sufﬁcient to detect a peak
VO2 difference of 2mL/min/kg with an SD of 2, with 90%
power and α = 0.05.
Results
Characteristics of the study group
Forty-two patients who fulﬁlled the study inclusion/exclusion
criteria were enrolled in the study: 19 patients received pla-
cebo and 23 received levosimendan. At study run-in, the
mean NYHA classes were 3.2 ± 0.4 and 3.3 ± 0.4 for placebo
and active treatment, respectively. The baseline characteris-
tics were well balanced between the two groups (Table 1).
The HF treatments were in accordance with international
guidelines (Table 1), and they were maintained during the
study.
Clinical, laboratory, and spirometry parameters
The infusions started approximately 3 h after the clinical,
blood, and spirometry tests had been completed, which
means after 48 to 72 h of clinical stabilization. The mean infu-
sion rates were 16 ± 4mL/h for placebo and 14 ± 4mL/h for
levosimendan (equivalent to 0.82μg/kg/min levosimendan)
(P = 0.34). The mean infusion durations were 31.3 ± 3.5 and
37.7 ± 4.0 h for placebo and active treatments, respectively
(P = 0.28). Clinical, blood, and spirometry parameters in the
two groups of patients before and 24 h after the end of the
treatment infusions are reported in Table 2. Before the infu-
sions, there were no signiﬁcant differences between the two
study groups for any of the investigated parameters, al-
though there was a tendency towards a worse kidney func-
tion in the placebo group.
Following the treatments, there was no signiﬁcant change in
the placebo group for the mean NYHA class (3.2 ± 0.4 to 3.1
± 0.5, P = 0.15), while it was signiﬁcantly reduced in the
levosimendan group (3.3 ± 0.4 to 2.1 ± 0.3, P< 0.001) (Figure 2).
BNP also showed no changes with the placebo infusion
(1042 ± 811 to 1043 ± 867 pg/mL, P = 0.9), but it was de-
creased signiﬁcantly with the levosimendan infusion (1163
± 897 to 509 ± 543 pg/mL, P <0.001) (Figure 3A).
Improvements in FEV1 and VC, but not in DLCO, were also
observed in the levosimendan-treated patients (Table 2).
Cardiopulmonary exercise test parameters
The pre-infusion and 24-h post-infusion CPET data are re-
ported in Table 3. A minor peak VO2 increase was observed
after the placebo treatment, although it did not reach statis-
tical signiﬁcance (P = 0.09), while the patients treated with
levosimendan showed a signiﬁcant peak VO2 improvement
(Figure 3B; Table 3; P = 0.005). Similarly, the peak workload
showed no change after placebo treatment, but it signiﬁ-
cantly increased after levosimendan (Table 3; P = 0.002). The
VE/VCO2 slope also showed no change after placebo treat-
ment, but it signiﬁcantly decreased after levosimendan
(Figure 3C; Table 3; P = 0.001).
There were some signiﬁcant correlations between the pre-
infusion and post-infusion BNP and peak VO2 changes for the
Table 1 Baseline characteristics of the study population, according to treatment group
Characteristic
Treatment group
P-valuesPlacebo (n=19) Levosimendan (n=23)
Male [n (%)] 16 (84) 19 (83) ns
Age (years) 68.2± 9 70.3± 9.4 ns
Diabetes [n (%)] 3 (16) 4 (17) ns
Hypertension [n (%)] 11 (58) 14 (61) ns
Current smoker [n (%)] 1 (5) 2 (8) ns
Ischaemic cardiomyopathy [n (%)] 11 (58) 12 (52) ns
Left ventricle ejection fraction (%) 25±6 25±7 ns
Telediastolic volume (mL) 213±78 187± 63 ns
Telesystolic volume (mL) 161±69 142± 59 ns
Pulmonary artery systolic pressure (mmHg) 48±13 45±14 ns
NYHA class 3.2± 0.4 3.3±0.4 ns
Angiotensin-converting enzyme inhibitors [n (%)] 11 (58) 15 (65) ns
Angiotensin receptor blockers [n (%)] 8 (42) 8 (35) ns
Aldosterone-blocking agents [n (%)] 14 (74) 18 (78) ns
β-blockers [n (%)] 19 (100) 23 (100) ns
Diuretics [n (%)] 19 (100) 23 (100) ns
Nitrates [n (%)] 6 (31) 7 (30) ns
Cardioaspirin [n (%)] 11 (58) 12 (52) ns
Data are expressed as means± standard deviation, or n and %.
NYHA, New York Heart Association; ns, not signiﬁcant.
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patients in the levosimendan treatment group. In particular,
the BNP reduction correlated with the reduction in the anaer-
obic threshold of VO2 (r =0.398; P< 0.01), the VE/VCO2
slope reduction (r =0.497; P< 0.001), and the VE/VO2 reduc-
tion (r =0.488; P< 0.001). Similarly, the peak VO2 increase
correlated with the VE/VCO2 slope reduction (r =0.463;
P< 0.002), the peak workload increase (r = 0.784; P< 0.001),
and the peak PetCO2 increase (r = 0.444; P< 0.004).
Discussion
In the present study, we assessed the effects of a single
levosimendan infusion vs. placebo in patients with ADHF,
using CPET. With the levosimendan treatment, in parallel
with a reduction in the resting BNP, there was an improve-
ment in lung mechanics, but not in DLCO. We also observed
a signiﬁcant increase in peak VO2 and a signiﬁcant decrease
in VE/VCO2 slope. Of note, BNP, peak VO2, and VE/VCO2
parameters were all associated with HF severity and progno-
sis. Moreover, an improvement in peak VO2 is considered a
pivotal marker to assess the efﬁcacy of a therapy, and it is
considered as a strong criterion to include, exclude, maintain,
or withdraw a subject from a heart-transplant list.31,32
The populations that have been studied by most of the
previous trials regarding inotropic agents were composed of
patients with worsening HF, for whom it is difﬁcult, if not
impossible, to perform evaluations of functional capacity.
Indeed, in this setting, any drug efﬁcacy evaluation is limited
to the clinical outcome, which is inﬂuenced by several uncon-
trolled variables, and to a few measured parameters and
mainly haemodynamic variables and BNP values.
The patients included in the present study were all admit-
ted to the HF Unit because of HF worsening, although when
they were enrolled in this study, their ADHF was under stabi-
lized conditions. We chose a peak VO2< 12mL/kg/min as the
cut-off for the inclusion in the present study because this is
the cut-off that has been used to assess patients who are
Table 2 Changes in the laboratory and spirometry parameters pre-infusion and post-infusion for the placebo and levosimendan
treatments
Parameter
Placebo
P-
value
Levosimendan
P-value
P-value
between
treatmentsaPre-infusion Post-infusion Pre-infusion Post-infusion
HR rest (bpm) 72.2±9.1 67± 9.1 0.04 72.9±10.4 78.4±13.8 0.015 0.002
Hb (g/dL) 12.4± 1.7 12.3±1.8 ns 12.4±1.5 12.2±1.5 ns ns
BNP (pg/mL) 1042±811 1043±867 ns 1163±897 510±543 <0.001 <0.001
Creatinine (mg/dL) 1.7± 0.6 1.8± 0.5 ns 1.5± 0.5 1.6±0.5 ns ns
BUN (mg/dL) 95±46 90± 28 ns 77±36 79±40 ns ns
FEV1 (L) 1.8± 0.4 1.89±0.4 ns 2.0± 0.53 2.1±0.6 0.02 ns
FEV1 (%pred) 70±14 71± 13 ns 79±17 85±20 0.01 ns
VC (L) 2.65±0.6 2.66±0.6 ns 2.7± 0.71 2.8±0.7 ns ns
VC (%pred) 76±16 75±13 ns 82±18 86±19 0.02 0.03
DLCO (mL/mmHg/min) 16.3± 3.9 16.9±3.9 ns 14.9±4.2 14.3±4.1 ns 0.003
DLCO (%pred) 66±12 68± 12 ns 64±16 61±14 ns ns
Va (L) 4.3± 0.8 4.4± 1.4 ns 4.3± 1.0 4.4±1.0 ns ns
Data are expressed as means± standard deviation.
BNP, brain natriuretic peptide; BUN, blood urea nitrogen; DLCO, lung diffusion for carbon monoxide adjusted for haemoglobin; FEV1,
forced expiratory volume in 1 s; HR, heart rate; Hb, haemoglobin; Va, alveolar volume; VC, vital capacity.
aAssessed by the infusion× treatment interaction.
Figure 2 New York Heart Association (NYHA) class changes with placebo (left) and levosimendan (right). ns, non-signiﬁcant; asterisk, P< 0.001.
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candidates for heart transplantation if they are under treat-
ment with β-blockers, as all of the patients in the present
study were.4,31
At present, there remain some controversies about the ef-
ﬁcacy of levosimendan in the setting of patients with ADHF.
Indeed, in a recent study, Altenberger et al.33 reported that
intermittent ambulatory treatment with levosimendan in pa-
tients with ADHF improved functional capacity, as evaluated
by 6-min walk test, and quality of life, although this did not
reach signiﬁcance. However, the dose of levosimendan used
by Altenberger et al.33 was the lowest that has been used
compared with other studies in the same patient population.
Our patients and those of Altenberger et al.33 shared some
similarities; that is, in both cases, the patients with HF were
able to exercise. However, there were also some differences
with the Altenberger et al.33 study, which included ambula-
tory patients who appeared likely to have had more
prolonged stabilization compared with those in the present
study. Moreover, we used a higher dose of levosimendan
than Altenberger et al.33 Finally, our study provides
favourable results, but it was limited to a single levosimendan
infusion, so that we do not know whether repeated infusions
will provide similar results.
In the present study, NYHA class and BNP signiﬁcantly
decreased after the levosimendan infusion. Both are rele-
vant clinical ﬁndings showing the efﬁcacy of levosimendan
infusion in this setting of ADHF patients. The NYHA class
and >50% BNP reduction were observed over a very short
time (2.5–3.0 days), and both are relevant and unexpected
in their extent for a population of clinically stable patients.
Previously, few reports have shown any reduction in BNP
after levosimendan infusion, although the previous observa-
tions were on unstable patients.19–22 Of note, the BNP re-
duction we report here showed strong correlations with
VO2, VE/VO2, and VE/VCO2 at the anaerobic threshold. This
conﬁrms the strong dependence of the anaerobic threshold
on the haemodynamic pattern.34,35 Resting heart rate in-
creased after levosimendan infusion and decreased with
placebo. The former is an expected ﬁnding for a
vasodilating drug as is levosimendan, while the limited
heart rate reduction with placebo is a likely effect of con-
comitant therapy.
FEV1, VC, and DLCO are reduced in chronic HF patients,
who usually show a restrictive pattern and alveolar capillary
membrane dysfunction.35 Indeed, DLCO has been reported
to correlate with HF prognosis and severity.6,35 In terms
of the spirometry data in the present study, we observed
a small but signiﬁcant improvement in the lung mechanics
in the levosimendan-treated patients, although there were
no changes in DLCO. In the HF lung, mechanical improve-
ments are frequently observed as a consequence of lung
ﬂuid reduction.36,37 However, we did not observe DLCO
changes. This ﬁnding is not unexpected, and indeed, the
same result has been observed shortly after ultraﬁltration,
where lung mechanics improved and DLCO was un-
changed.35 Similar ﬁndings have been reported during
high-altitude exposure, where DLCO decreases shortly after
high-altitude exposure because of lung ﬂuid accumulation,
whereas restoration of gas exchange needs prolonged
exposure.38,39
To the best of our knowledge, CPET has never been per-
formed before to assess levosimendan efﬁcacy. We observed
a relevant and parallel amelioration of all of the major CPET-
derived parameters after levosimendan infusion. Of note, VO2
at peak exercise and at anaerobic threshold, VE/VCO2 slope,
and PetCO2 are strong tools to assess HF severity.
3 In con-
trast, in the placebo group, there was only a trend toward
VO2 increase both at anaerobic threshold and under peak
Figure 3 Changes in B-type natriuretic peptide (BNP) (A), peak oxygen
consumption (VO2) (B), and ventilation/CO2 production (VE/VCO2) slope
(C) in patients treated with placebo and levosimendan. *, P< 0.02.
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exercise, which is likely to be an effect of concomitant therapy
for post-acute decompensation.
A few study limitations should be acknowledged here.
Firstly, we limited our observation to a single drug infusion,
so that we do not know if it applies to subjects needing re-
peated levosimendan infusions. Secondly, we have per-
formed a short-term evaluation of levosimendan infusion.
Therefore, we cannot say whether its beneﬁt persists and
how long it lasts in our population. Thirdly, we studied pa-
tients who were able to perform CPET. Accordingly, we ex-
cluded patients with more severe HF. Finally, our patients
were free from HF comorbidities, which might have per se in-
ﬂuenced their outcomes.
In conclusion, to the best of our knowledge, the present
study is the ﬁrst to describe the effects of levosimendan in
terms of CPET. Our results show that levosimendan pro-
moted peak VO2 and VE/VCO2 slope amelioration in paral-
lel with a reduction in BNP. Our observations provide the
basis for the use of levosimendan in the post-acute phase
of HF. Although the present study was limited to a single
levosimendan infusion, it now provides a strong rationale
to test the effects of multiple infusions of levosimendan
at regular intervals in a population of patients with ADHF.
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